Chiva - La Paz_TN_Breast_Cancer

Clustergrammer Heatmap
Flag FileDownloadCreatedProteinsPeptidesPrecursorsTransitionsReplicates
160706_LaPAZ_PRM_Refined_yellow_green_2017-03-29_09-23-36.sky.zip (133 MB)2017-10-2538891691,112143
160706_LaPAZ_PRM_Refined_green_2017-03-29_09-28-25.sky.zip (130 MB)2017-10-25275499648143
Targeted proteomics in triple negative breast cancer on FFPE samples

  • Organism: Homo sapiens
  • Instrument: Orbitrap Fusion Lumos
  • SpikeIn: Yes
Abstract
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and usually requires the administration of adjuvant chemotherapy after surgery but even with this treatment many patients still suffer from a relapse. The main objective of this study was to identify proteomics-based biomarkers that predict the response to standard adjuvant chemotherapy, so that patients at are not going to benefit from it can be offered therapeutic alternatives.
Experiment Description
We analyzed the proteome of a retrospective series of formalin-fixed, paraffin-embedded TNBC tissue applying high-throughput label-free quantitative proteomics. We identified several protein signatures with predictive value, which were validated with quantitative targeted proteomics (PRM) in an independent cohort of patients and further evaluated in publicly available transcriptomics data.
Sample Description
The targeted proteomics cohort includes one hundred and fourteen samples from patients diagnosed of triple negative breast cancer were retrieved from I+12 Biobank (RD09/0076/00118) and from IdiPAZ Biobank (RD09/0076/00073), both integrated in the Spanish Hospital Biobank Network (RetBioH; www.redbiobancos.es) between 1997 and 2012. The histopathological features of each sample were reviewed by an experienced pathologist to confirm diagnosis and tumor content. Eligible samples had to include at least 50% of tumor cells.
Created on 10/25/17, 9:56 AM